You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Emodin as a complementary dietary therapy to reduce toxicity of 5 fluorouracil

    SBC: AcePre, LLC            Topic: NCCIH

    PROJECT SUMMARYfluorouracilFUhas been the first choice chemotherapy drug for colorectal cancerCRCfor many yearshoweverits clinical utility remains hindered by hematopoietic and gastrointestinal toxicities resulting from its non selectivitySide effects include fatigueloss of appetiteand diarrhea among othersall of which can lead to reduced quality of lifeThe economic burden associated with chemothe ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of small molecule SERCA2b activators to inhibit neuron loss in Alzheimer's disease

    SBC: Neurodon LLC            Topic: NIA

    Alzheimer s diseaseADis an immense national public health burdenIt is theth leading cause of death in the US with overmillion Americans sufferingand costs of over $billion in health care and related expensesThis patient population is expected to almost triple over the nextyearsDespite this urgent needthere are currently no disease modifying agents approvedNeuron loss is the only physiological phen ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Mitigating Injurious Falls in Older Adults Through Non-Injurious Fall and Gait Analysis From Floor Vibrations

    SBC: ADVANCED SMART SYSTEMS AND EVALUATION TECHNOLOGIES, LLC            Topic: NIA

    Project Summary and Abstract Falls are the leading cause of death due to injuryThis simple motion is so common thatof community dwelling older adultsandof long term care facilities will experience a fall in the coming yearThe risk of falling substantially increases for those having Alzheimer s disease and related dementiasand those with Parkinson s diseaseThe financial burden is significant with f ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Tissue Oxygenation in Small Retinal Vessels

    SBC: AEON IMAGING, LLC            Topic: W

    Summary Recentlywe found extensive remodeling of the microvasculature of the retinaoccurring in some diabetic patients much earlier than expectedThis provides the potential for novel biomarkers to improve classification of patients for management and cost effective testing of therapiesHoweverthe equipment is too expensive for most clinics and small practicesThese early retinal microvascular change ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. Targeted Nanotherapy to Donor Organ Endothelia Modulates Early Immune Responses and Protects Against Late Graft Failure

    SBC: ToleRaM NanoTech LLC            Topic: NIBIB

    ABSTRACT Transplantation is an accepted and highly successful therapy for end stage organ diseaseWhile success rates and survival have risen steadilydue largely to improved immunosuppression regimesthere is a growing appreciation that damage and inflammation that occur early in the life of the graftsignificantly impact chronic rejection and thus long term survivalCentral to these early event injur ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  6. Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate

    SBC: NeuroFx, Inc.            Topic: 300

    ABSTRACT Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of incidence of AKIno therapy currently existsother than supportiv ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Development of fully integrated electrochemical device for detecting metals in biological fluids

    SBC: Bioanalytical Systems, Inc.            Topic: NIEHS

    Exposure to toxic levels of metals causes significant negative chronic health problems in the exposed populationsDuring and after exposuremetals such as manganeseleadnickelmercuryetcare present in biological fluidsA fully integrated wearable device would enable real time monitoring of exposure levelsThis would quickly alert those exposed to toxic concentrations of metals and mitigate the chronic h ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. Software and services to advance dose-response modeling in chemical risk assesment

    SBC: KS and Associates LLC            Topic: NCATS

    PROJECT SUMMARY Chemical risk assessment has been widely applied in chemical industry as a necessary step to get new commercial chemicals registeredand in governmental agencies as a critical procedure to evaluate the toxicity of chemicals in order to properly regulate them to protect human health and the environmentThe Lautenberg Chemical Safety Act further strengthens the importance of chemical r ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. Proteasome inhibitor re-sensitizing molecules for treatment of refractory multiple myeloma

    SBC: Leukogene Therapeutics Inc.            Topic: 102

    Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...

    STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
  10. Chronic intrapulmonary delivery of a novel small molecule Wnt/beta-catenin inhibitor for Idiopathic Pulmonary Fibrosis

    SBC: BETA CAT PHARMACEUTICALS, INC.            Topic: NHLBI

    Project Summary Idiopathic pulmonary fibrosisIPFis a devastatingprogressive disease with no known cure and no treatment that convincingly alters the disease course or significantly improves mortalityThe objective of this proposal is the development of nebulized delivery of the small molecule inhibitor of Wntcatenin signalingBCfor Idiopathic Pulmonary FibrosisPre clinical studies in rodentsdogsand ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government